个人中心 - 老虎社区

JojoFu

IP属地：未知

帖子 · 10帖子 · 10
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- JojoFuJojoFu
  ·2021-05-23
  Wow
  非常抱歉，此主贴已删除
  176 评论
  2
  分享
  举报
- JojoFuJojoFu
  ·2021-05-22
  Like
  非常抱歉，此主贴已删除
  447 1
  2
  分享
  举报
- JojoFuJojoFu
  ·2021-05-14
  Nice!!!
  Ocugen Has a Longer Road To Paying off Than People Think
  Good news from Ocugen has been met with a wave of selling in OCGN stock. I’ve long been skeptical t
  Ocugen Has a Longer Road To Paying off Than People Think
  362 1
  5
  分享
  举报
- JojoFuJojoFu
  ·2021-04-26
  Ooooo wow
  Philips EPS beats by €0.02, misses on revenue
  Philips：Q1 Non-GAAP EPS of €0.28beats by €0.02; GAAP EPS of -€0.04. Revenue of €3.83B (+3.8% Y/Y)mis
  Philips EPS beats by €0.02, misses on revenue
  199 2
  1
  分享
  举报
- JojoFuJojoFu
  ·2021-04-23
  What affects cryptocurrency
  257 评论
  点赞
  分享
  举报
- JojoFuJojoFu
  ·2021-04-20
  $Chart(GTLS)$Sounds good
  269 评论
  点赞
  分享
  举报
- JojoFuJojoFu
  ·2021-04-19
  Yea sounds good
  Private equity firm Siris tables $864.6 million bid for UK's Equiniti
  (Reuters) - Siris Capital has submitted a non-binding proposal to buy British outsourcer Equiniti fo
  Private equity firm Siris tables $864.6 million bid for UK's Equiniti
  373 1
  2
  分享
  举报
- JojoFuJojoFu
  ·2021-04-19
  I think this is a good investment.
  非常抱歉，此主贴已删除
  279 评论
  点赞
  分享
  举报
- JojoFuJojoFu
  ·2021-04-19
  Wow what a merger
  非常抱歉，此主贴已删除
  313 2
  2
  分享
  举报
- JojoFuJojoFu
  ·2021-04-19
  Any advice for a newcomer?
  222 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581631735901112","uuid":"3581631735901112","gmtCreate":1618538793701,"gmtModify":1618825210183,"name":"JojoFu","pinyin":"jojofu","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":34,"tweetSize":10,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":133354677,"gmtCreate":1621710323799,"gmtModify":1634187058019,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/133354677","repostId":"2137290909","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":139626341,"gmtCreate":1621616994683,"gmtModify":1634187617101,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/139626341","repostId":"1153943475","repostType":4,"isVote":1,"tweetType":1,"viewCount":447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":198134579,"gmtCreate":1620945579191,"gmtModify":1634195172980,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Nice!!!","listText":"Nice!!!","text":"Nice!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/198134579","repostId":"1118899332","repostType":4,"repost":{"id":"1118899332","kind":"news","pubTimestamp":1620918983,"share":"https://www.laohu8.com/m/news/1118899332?lang=&edition=full","pubTime":"2021-05-13 23:16","market":"us","language":"en","title":"Ocugen Has a Longer Road To Paying off Than People Think","url":"https://stock-news.laohu8.com/highlight/detail?id=1118899332","media":"InvestorPlace","summary":"Good news from Ocugen has been met with a wave of selling in OCGN stock.\n\nI’ve long been skeptical t","content":"<blockquote>\n <b>Good news from Ocugen has been met with a wave of selling in OCGN stock.</b>\n</blockquote>\n<p>I’ve long been skeptical toward<b>Ocugen</b>(NASDAQ:<b><u>OCGN</u></b>) stock. To some degree, I still am.</p>\n<p>OCGN is pushed as a vaccine play, thanks to its partnership with India’s<b>Bharat Biotech</b>, but some investors miss the fact that the partnership is skewed sharply in Bharat’s favor.</p>\n<p>Ocguen only has rights to distribution in the U.S. It must do all the heavy lifting (financially and operationally) to get Bharat’s Covaxin to market. In return, the company receives just45% of any profits.</p>\n<p>So the idea that OCGN stock is the next<b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>) is quite a stretch. The geographical limitations on the Covaxin license, the past failures in the legacy ocular pipeline, and the profit-sharing agreement leave OCGN at a seeming disadvantage to even the likes of<b>Inovio</b>(NASDAQ:<b><u>INO</u></b>) or<b>Sorrento Therapeutics</b>(NASDAQ:<b><u>SRNE</u></b>).</p>\n<p>The push/pull in OCGN stock reflects these two facts. When Bharat released positive data last month, OCGN soared. It’s since dropped 41% in a matter of days.</p>\n<p>After this most recent fade, however, OCGN does look at least intriguing, even to this skeptic.</p>\n<p>There’s still a lot of work to do, certainly. But Ocugen has the cash and the product. If it can execute, there’s potential upside, even given the constraints of the Bharat deal.</p>\n<p><b>Good News Gets Punished?</b></p>\n<p>I can certainly see how the trading in OCGN over the past few months, and few weeks, would be confusing.</p>\n<p>After all, it seems like Ocugen has delivered mostly good news over that stretch. Data from Bharat on Covaxin gets more detailed and seemingly more positive.</p>\n<p>The second interim results released in April showed100% protection against hospitalization. OCGN soared on that news. Early this month, Bharat showedeffectiveness against the key variantsthat have alarmed scientists of late.</p>\n<p>OCGN actually trades below where it did in early February, though, after the stock tripled following an equity offeringpriced above the market. It will open today at around $8.60.</p>\n<p>Now, comparing OCGN to past peaks has an obvious problem: the stock has seen bubbly trading both in February and the second half of April. Some level of correction was needed in both instances.</p>\n<p>That said, there is a case that the most recent selling has gone a little too far (and indeed shares have found a temporary bottom at the moment). With OCGN approaching $9, the math here can work.</p>\n<p><b>The Math for OCGN Stock</b></p>\n<p>On March 31, Ocugen had $45 million in cash, and 188.2 million shares outstanding. A $100 million equity offeringpriced at $10followed in April.</p>\n<p>Ocugen should close Q2 with about $135 million in cash, assuming its burn rate accelerates as it builds out the infrastructure for Covaxin. That’s probably, though not definitely, enough to get the vaccine to market. Substantial dilution thus seems unlikely.</p>\n<p>Ocugen has a fully diluted market capitalization of nearly $1.8 billion. (That figure includes about 10 million options and warrants outstanding at March 31.)</p>\n<p>So there’s a simplistic question to ask about OCGN stock: can the company generate $2 billion in profit off Covaxin?</p>\n<p><b>Looking to Moderna</b></p>\n<p>That’s likely the minimum required to see any upside here. It’s difficult to assign any material value to the company’s owned pipeline, given the company had a market capitalization below $50 million before the Bharat deal was signed.</p>\n<p>After all, $2 billion is a reasonably high bar. Again, Ocugen only gets 45% of the profits, so Covaxin must generate $4.5 billion or so in earnings.</p>\n<p>We can see from Moderna earnings what the profit profile might look like. Treating previously produced inventory at cost, Moderna’sgross margins were 78%in the first quarter.</p>\n<p>Just to get to $4.5 billion in gross profit, then, Covaxin needs to generate nearly $6 billion in revenue.</p>\n<p>At Moderna’s $19 per dose price, we’re looking at about 300 million doses even before operating expenses. Add in those expenses (it’s tough to estimate, but a few hundred million seems in the ballpark) and Covaxin perhaps needs to move something in the range of 350 million doses.</p>\n<p>Can Covaxin hit that bogey? It does seem tough.</p>\n<p>Moderna is guiding for 200 million to 250 million doses just in the second quarter, but much of that supply is going to international markets.</p>\n<p>For OCGN stock to rise from here, Covaxin probably needs to be one of the most commonly used vaccines domestically, while competing not only with Moderna, but<b>Pfizer</b>(NYSE:<b><u>PFE</u></b>),<b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>) and presumably others.</p>\n<p>That’s the bet when it comes to OCGN. Honestly, it’s not a bet I’m terribly interested in taking. But with OCGN stock pulling back, reasonable investors probably can disagree.</p>\n<p><i>On the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Has a Longer Road To Paying off Than People Think</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Has a Longer Road To Paying off Than People Think\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-13 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/05/confusing-trading-leaves-ocgn-stock-interesting/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Good news from Ocugen has been met with a wave of selling in OCGN stock.\n\nI’ve long been skeptical towardOcugen(NASDAQ:OCGN) stock. To some degree, I still am.\nOCGN is pushed as a vaccine play, thanks...</p>\n\n<a href=\"https://investorplace.com/2021/05/confusing-trading-leaves-ocgn-stock-interesting/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/05/confusing-trading-leaves-ocgn-stock-interesting/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1118899332","content_text":"Good news from Ocugen has been met with a wave of selling in OCGN stock.\n\nI’ve long been skeptical towardOcugen(NASDAQ:OCGN) stock. To some degree, I still am.\nOCGN is pushed as a vaccine play, thanks to its partnership with India’sBharat Biotech, but some investors miss the fact that the partnership is skewed sharply in Bharat’s favor.\nOcguen only has rights to distribution in the U.S. It must do all the heavy lifting (financially and operationally) to get Bharat’s Covaxin to market. In return, the company receives just45% of any profits.\nSo the idea that OCGN stock is the nextModerna(NASDAQ:MRNA) is quite a stretch. The geographical limitations on the Covaxin license, the past failures in the legacy ocular pipeline, and the profit-sharing agreement leave OCGN at a seeming disadvantage to even the likes ofInovio(NASDAQ:INO) orSorrento Therapeutics(NASDAQ:SRNE).\nThe push/pull in OCGN stock reflects these two facts. When Bharat released positive data last month, OCGN soared. It’s since dropped 41% in a matter of days.\nAfter this most recent fade, however, OCGN does look at least intriguing, even to this skeptic.\nThere’s still a lot of work to do, certainly. But Ocugen has the cash and the product. If it can execute, there’s potential upside, even given the constraints of the Bharat deal.\nGood News Gets Punished?\nI can certainly see how the trading in OCGN over the past few months, and few weeks, would be confusing.\nAfter all, it seems like Ocugen has delivered mostly good news over that stretch. Data from Bharat on Covaxin gets more detailed and seemingly more positive.\nThe second interim results released in April showed100% protection against hospitalization. OCGN soared on that news. Early this month, Bharat showedeffectiveness against the key variantsthat have alarmed scientists of late.\nOCGN actually trades below where it did in early February, though, after the stock tripled following an equity offeringpriced above the market. It will open today at around $8.60.\nNow, comparing OCGN to past peaks has an obvious problem: the stock has seen bubbly trading both in February and the second half of April. Some level of correction was needed in both instances.\nThat said, there is a case that the most recent selling has gone a little too far (and indeed shares have found a temporary bottom at the moment). With OCGN approaching $9, the math here can work.\nThe Math for OCGN Stock\nOn March 31, Ocugen had $45 million in cash, and 188.2 million shares outstanding. A $100 million equity offeringpriced at $10followed in April.\nOcugen should close Q2 with about $135 million in cash, assuming its burn rate accelerates as it builds out the infrastructure for Covaxin. That’s probably, though not definitely, enough to get the vaccine to market. Substantial dilution thus seems unlikely.\nOcugen has a fully diluted market capitalization of nearly $1.8 billion. (That figure includes about 10 million options and warrants outstanding at March 31.)\nSo there’s a simplistic question to ask about OCGN stock: can the company generate $2 billion in profit off Covaxin?\nLooking to Moderna\nThat’s likely the minimum required to see any upside here. It’s difficult to assign any material value to the company’s owned pipeline, given the company had a market capitalization below $50 million before the Bharat deal was signed.\nAfter all, $2 billion is a reasonably high bar. Again, Ocugen only gets 45% of the profits, so Covaxin must generate $4.5 billion or so in earnings.\nWe can see from Moderna earnings what the profit profile might look like. Treating previously produced inventory at cost, Moderna’sgross margins were 78%in the first quarter.\nJust to get to $4.5 billion in gross profit, then, Covaxin needs to generate nearly $6 billion in revenue.\nAt Moderna’s $19 per dose price, we’re looking at about 300 million doses even before operating expenses. Add in those expenses (it’s tough to estimate, but a few hundred million seems in the ballpark) and Covaxin perhaps needs to move something in the range of 350 million doses.\nCan Covaxin hit that bogey? It does seem tough.\nModerna is guiding for 200 million to 250 million doses just in the second quarter, but much of that supply is going to international markets.\nFor OCGN stock to rise from here, Covaxin probably needs to be one of the most commonly used vaccines domestically, while competing not only with Moderna, butPfizer(NYSE:PFE),Johnson & Johnson(NYSE:JNJ) and presumably others.\nThat’s the bet when it comes to OCGN. Honestly, it’s not a bet I’m terribly interested in taking. But with OCGN stock pulling back, reasonable investors probably can disagree.\nOn the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article.","news_type":1},"isVote":1,"tweetType":1,"viewCount":362,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":374156318,"gmtCreate":1619431125934,"gmtModify":1634273553760,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Ooooo wow","listText":"Ooooo wow","text":"Ooooo wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/374156318","repostId":"1129390203","repostType":4,"repost":{"id":"1129390203","kind":"news","pubTimestamp":1619429904,"share":"https://www.laohu8.com/m/news/1129390203?lang=&edition=full","pubTime":"2021-04-26 17:38","market":"us","language":"en","title":"Philips EPS beats by €0.02, misses on revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=1129390203","media":"seekingalpha","summary":"Philips：Q1 Non-GAAP EPS of €0.28beats by €0.02; GAAP EPS of -€0.04.\nRevenue of €3.83B (+3.8% Y/Y)mis","content":"<li>Philips：Q1 Non-GAAP EPS of&nbsp;€0.28beats by €0.02; GAAP EPS of -€0.04.</li>\n<li>Revenue of&nbsp;€3.83B (+3.8% Y/Y)misses by €410M.</li>\n<li>Comparable order intake decreased 5%.</li>\n<li>The company recorded a strong 9% comparable sales growth and Adjusted EBITA margin improved 390 bps to 9.5%.</li>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips EPS beats by €0.02, misses on revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips EPS beats by €0.02, misses on revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-26 17:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3685331-philips-eps-beats-by-002-misses-on-revenue><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Philips：Q1 Non-GAAP EPS of €0.28beats by €0.02; GAAP EPS of -€0.04.\nRevenue of €3.83B (+3.8% Y/Y)misses by €410M.\nComparable order intake decreased 5%.\nThe company recorded a strong 9% comparable ...</p>\n\n<a href=\"https://seekingalpha.com/news/3685331-philips-eps-beats-by-002-misses-on-revenue\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PHG":"飞利浦"},"source_url":"https://seekingalpha.com/news/3685331-philips-eps-beats-by-002-misses-on-revenue","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129390203","content_text":"Philips：Q1 Non-GAAP EPS of €0.28beats by €0.02; GAAP EPS of -€0.04.\nRevenue of €3.83B (+3.8% Y/Y)misses by €410M.\nComparable order intake decreased 5%.\nThe company recorded a strong 9% comparable sales growth and Adjusted EBITA margin improved 390 bps to 9.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":199,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":376740809,"gmtCreate":1619152111201,"gmtModify":1634288149225,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"What affects cryptocurrency&nbsp;","listText":"What affects cryptocurrency&nbsp;","text":"What affects cryptocurrency","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/376740809","isVote":1,"tweetType":1,"viewCount":257,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373782522,"gmtCreate":1618883996166,"gmtModify":1631888715939,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GTLS\">$Chart(GTLS)$</a>Sounds good","listText":"<a href=\"https://laohu8.com/S/GTLS\">$Chart(GTLS)$</a>Sounds good","text":"$Chart(GTLS)$Sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373782522","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373377865,"gmtCreate":1618827273557,"gmtModify":1634290595675,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Yea sounds good","listText":"Yea sounds good","text":"Yea sounds good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/373377865","repostId":"1127086051","repostType":4,"repost":{"id":"1127086051","kind":"news","pubTimestamp":1618824711,"share":"https://www.laohu8.com/m/news/1127086051?lang=&edition=full","pubTime":"2021-04-19 17:31","market":"us","language":"en","title":"Private equity firm Siris tables $864.6 million bid for UK's Equiniti","url":"https://stock-news.laohu8.com/highlight/detail?id=1127086051","media":"Reuters","summary":"(Reuters) - Siris Capital has submitted a non-binding proposal to buy British outsourcer Equiniti fo","content":"<p>(Reuters) - Siris Capital has submitted a non-binding proposal to buy British outsourcer Equiniti for 624.3 million pounds ($864.6 million) in cash, the U.S. equity firm said on Monday, confirming months of media speculation about a bid.</p><p>Equiniti, shares of which rose by as much a fifth, said it had received a \"highly conditional non-binding proposal\" from Siris earlier in the day.</p><p>The 170-pence-per-share bid is Siris' fifth approach to Equiniti, Sky News reported, adding its most recent attempt was in January. (https://bit.ly/32r5Xwx)</p><p>Equiniti, which works with more than two thirds of the companies listed on the FTSE 100 index, said its board would evaluate the offer and \"strongly advised\" its shareholders not to take action in the meantime.</p><p>Siris said further announcements will be made, but there is no certainty that a formal offer will be made. It has until May 17 to make a firm bid or walk away under the UK's takeover rules.</p><p>Equiniti's stock price has soared 19% since reports of takeover interest first emerged in early February. Shares were up another 16% at 158.8 pence by 0829 GMT.</p><p>Listed on the UK mid-cap index, the company holds 70 million shareholder records, sends 90 billion pounds in payments each year and looks after 1.1 million share plan investors, according to its website.</p><p>In January, Equiniti said it was in discussions to divest a key part of its financial services.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Private equity firm Siris tables $864.6 million bid for UK's Equiniti</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrivate equity firm Siris tables $864.6 million bid for UK's Equiniti\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-19 17:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/private-equity-firm-siris-tables-091958958.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Siris Capital has submitted a non-binding proposal to buy British outsourcer Equiniti for 624.3 million pounds ($864.6 million) in cash, the U.S. equity firm said on Monday, confirming ...</p>\n\n<a href=\"https://finance.yahoo.com/news/private-equity-firm-siris-tables-091958958.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/private-equity-firm-siris-tables-091958958.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127086051","content_text":"(Reuters) - Siris Capital has submitted a non-binding proposal to buy British outsourcer Equiniti for 624.3 million pounds ($864.6 million) in cash, the U.S. equity firm said on Monday, confirming months of media speculation about a bid.Equiniti, shares of which rose by as much a fifth, said it had received a \"highly conditional non-binding proposal\" from Siris earlier in the day.The 170-pence-per-share bid is Siris' fifth approach to Equiniti, Sky News reported, adding its most recent attempt was in January. (https://bit.ly/32r5Xwx)Equiniti, which works with more than two thirds of the companies listed on the FTSE 100 index, said its board would evaluate the offer and \"strongly advised\" its shareholders not to take action in the meantime.Siris said further announcements will be made, but there is no certainty that a formal offer will be made. It has until May 17 to make a firm bid or walk away under the UK's takeover rules.Equiniti's stock price has soared 19% since reports of takeover interest first emerged in early February. Shares were up another 16% at 158.8 pence by 0829 GMT.Listed on the UK mid-cap index, the company holds 70 million shareholder records, sends 90 billion pounds in payments each year and looks after 1.1 million share plan investors, according to its website.In January, Equiniti said it was in discussions to divest a key part of its financial services.","news_type":1},"isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373355154,"gmtCreate":1618824635478,"gmtModify":1634290664448,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"I think this is a good investment.&nbsp;","listText":"I think this is a good investment.&nbsp;","text":"I think this is a good investment.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373355154","repostId":"2128862412","repostType":4,"isVote":1,"tweetType":1,"viewCount":279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373312901,"gmtCreate":1618821443503,"gmtModify":1634290690615,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Wow what a merger","listText":"Wow what a merger","text":"Wow what a merger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/373312901","repostId":"1111461366","repostType":4,"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":373316514,"gmtCreate":1618821370138,"gmtModify":1634290690855,"author":{"id":"3581631735901112","authorId":"3581631735901112","name":"JojoFu","avatar":"https://static.tigerbbs.com/d4446865a5aea70dcd654f6c19a08151","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581631735901112","authorIdStr":"3581631735901112"},"themes":[],"htmlText":"Any advice for a newcomer?","listText":"Any advice for a newcomer?","text":"Any advice for a newcomer?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/373316514","isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}